BridgeBio Pharma Partners with Kyowa Kirin to Develop and Commercialize Infigratinib to Treat Skeletal Dysplasias in Japan
Shots:
- Kyowa Kirin signed an agreement with BridgeBio’s affiliate, QED Therapeutics under which, Kyowa Kirin received an exclusive license to develop & commercialize infigratinib to treat ACH, hypochondroplasia & other skeletal dysplasias across Japan
- As per the agreement, BridgeBio will receive an up front payment of $100M & is eligible to receive potential milestone-based payments, plus high-twenties percent royalties
- Infigratinib (small molecule FGFR3 inhibitor) is currently being evaluated in a P-III (PROPEL 3) clinical trial for safety & efficacy among children & adolescents with ACH. Additionally, BridgeBio also expects to initiate an observational study (ACCEL) evaluating infigratinib in hypochondroplasia by H1’24
Ref: BridgeBio | Image: BridgeBio
Related News:- Kyowa Kirin to Acquire Orchard Therapeutics for ~$477.6M
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Shivani is a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
